| Literature DB >> 17419001 |
Christine Mrakotsky1, Bruce Masek, Joseph Biederman, Darcy Raches, Olivia Hsin, Peter Forbes, Carl de Moor, David Ray DeMaso, Joseph Gonzalez-Heydrich.
Abstract
Mirtazapine is indicated for major depression and used for anxiety in adults; however, little is known about its application in pediatric populations. This is an 8-week open-label pilot study of mirtazapine in children with social phobia age 8-17 years. Primary outcomes were symptom improvement based on clinician rating and self-report, as well as tolerability based on rates of discontinuation due to adverse effects. Fifty-six percent (10/18) responded to treatment, 17% (3/18) achieved full remission. Social phobia symptoms improved significantly during the first 2 weeks of treatment, as did comorbid symptoms of depression and anxiety. Eleven patients (61%) did not complete all 8 weeks of treatment; four patients (22%) discontinued due to adverse effects including fatigue and irritability. The others discontinued due to study burden (28%), insufficient response (6%), or to pursue herbal treatment (6%). Significant weight gain was observed. Larger controlled trials are needed to further evaluate efficacy and safety.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17419001 DOI： 10.1016/j.janxdis.2007.01.005
Source DB: PubMed Journal: J Anxiety Disord ISSN： 0887-6185